← Back to Search

Monoclonal Antibodies

Axitinib for Liver Cancer

Phase 2
Waitlist Available
Led By David Hsieh, MD
Research Sponsored by University of Texas Southwestern Medical Center
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Patient must have a histologically confirmed diagnosis consistent with HCC; known fibrolamellar HCC, or combined HCC-cholangiocarcinoma will be excluded.
Patients with locally advanced or metastatic disease must have disease deemed not amenable to surgical and/or locoregional therapies or patients who have progressed following surgical and/or locoregional therapies.
Timeline
Screening 3 weeks
Treatment Varies
Follow Up study treatment will continue until disease progression, unacceptable toxicity, death, or discontinuation from the study treatment for any other reason up to 48 months.
Awards & highlights

Study Summary

This trial shows that for some types of cancer, a new immunotherapy drug can help to fight the disease even after the tumor has grown.

Eligible Conditions
  • Liver Cancer

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~study treatment will continue until disease progression, unacceptable toxicity, death, or discontinuation from the study treatment for any other reason up to 48 months.
This trial's timeline: 3 weeks for screening, Varies for treatment, and study treatment will continue until disease progression, unacceptable toxicity, death, or discontinuation from the study treatment for any other reason up to 48 months. for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Response Rate of Combination Therapy
Secondary outcome measures
6-month Progression-free Survival
Disease Control Rate
Duration of Response
+3 more

Side effects data

From 2019 Phase 2 trial • 13 Patients • NCT02129647
30%
Mucositis
10%
nausea
10%
Fatigue
10%
Rash
100%
80%
60%
40%
20%
0%
Study treatment Arm
Axitinib

Trial Design

1Treatment groups
Experimental Treatment
Group I: Axitinib / Avelumab /BavituximabExperimental Treatment3 Interventions
Axitinib 5 mg PO BID Avelumab 10 mg/kg IV every 2 weeks (2 doses in a 4-week cycle) Bavituximab 3 mg/kg IV every 1 week (4 doses in a 4-week cycle) Study treatment will continue until disease progression, unacceptable toxicity, death, or discontinuation from the study treatment for any other reason.
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Axitinib
2020
Completed Phase 2
~3050
Avelumab
2018
Completed Phase 2
~2450
Bavituximab
2011
Completed Phase 2
~300

Find a Location

Who is running the clinical trial?

University of Texas Southwestern Medical CenterLead Sponsor
1,039 Previous Clinical Trials
1,048,098 Total Patients Enrolled
4 Trials studying Liver Cancer
5,606 Patients Enrolled for Liver Cancer
PfizerIndustry Sponsor
4,556 Previous Clinical Trials
10,907,682 Total Patients Enrolled
3 Trials studying Liver Cancer
340 Patients Enrolled for Liver Cancer
David Hsieh, MDPrincipal InvestigatorAssistant Professor
3 Previous Clinical Trials
298 Total Patients Enrolled
1 Trials studying Liver Cancer
58 Patients Enrolled for Liver Cancer

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

How many volunteers are participating in the research?

"Affirmative. Records on clinicaltrials.gov demonstrate that this research project, which was first published in November 4th 2022, is actively recruiting candidates. Approximately 29 individuals have to be enrolled from one medical clinic."

Answered by AI

Has Axitinib been officially sanctioned by the FDA?

"Axitinib was assessed with a score of 2 on the safety scale due to Phase 2 trial data that suggests some safety, yet no evidence supporting efficacy."

Answered by AI

Are volunteers still being accepted to participate in this investigation?

"Data hosted on clinicaltrials.gov supports the notion that this medical trial is recruiting volunteers as of November 4th 2022, which was also when the last edits to its information were made."

Answered by AI
~0 spots leftby Mar 2025